PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

被引：6
|
作者：
Pascual, Javier
MacPherson, Iain R.
Armstrong, Anne Caroline
Ward, Sarah Emily
Parmar, Mona
Turner, Alison Joanne
Bye, Hannah
Proszek, Paula
Dodson, Andrew
Garcia-Murillas, Isaac
King, Jenny
Hall, Emma
Finneran, Laura
Lopez, Juanita Suzanne
Okines, Alicia Frances Clare
Ring, Alistair E.
Turner, Nicholas C.
机构：
[1] Royal Marsden Hosp, London, England
[2] Inst Canc Res, London, England
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[5] Inst Canc Res, Sutton, Surrey, England
[6] Royal Marsden Inst Canc Res, London, England
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Inst Canc Res, Clin Trials & Stat Unit, London, England
[9] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1051
引用
收藏
页数：2
相关论文
共 46 条
  • [31] Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
    Dickler, M. N.
    Saura, C.
    Oliveira, M.
    Richards, D. A.
    Krop, I. E.
    Cervantes, A.
    Stout, T. J.
    Jin, H.
    Savage, H. M.
    Wilson, T. R.
    Baselga, J.
    CANCER RESEARCH, 2017, 77
  • [32] A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR plus ) advanced breast cancer (BC).
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Stout, Thomas
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER plus ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
    Turner, N.
    Alarcon, E.
    Armstrong, A.
    Philco, M.
    Lopez Chuken, Y. A.
    Sablin, M-P.
    Tamura, K.
    Gomez Villanueva, A.
    Perez-Fidalgo, J. A.
    Foxley, A.
    Lindemann, J.
    Maudsley, R.
    Outhwaite, E.
    Pass, M.
    Rugman, P.
    Schiavon, G.
    Oliveira, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Exploratory analysis of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER-2) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) plus FUL but not TAS plus FUL in SANDPIPER
    Johnson, Radia M.
    Liu, Bonnie
    Cortes, Javier
    Dent, Susan
    Harbeck, Nadia
    Krop, Ian E.
    Jacot, William
    Yauch, Robert L.
    Stout, Thomas J.
    Schimmoller, Frauke
    Gendreau, Steven
    Wilson, Timothy R.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Olivera, Mafalda
    Jhaveri, Komal
    Juric, Dejan
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Saura, Cristina
    CANCER RESEARCH, 2021, 81 (04)
  • [36] MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
    Piccart, Martine
    Hennequin, Audrey
    Borrego, Manuel Ruiz
    Escriva-De-Romani, Santiago
    Williams, Anja
    Rodriguez, Begona Jimenez
    Del Conte, Gianluca
    Howell, Sacha J.
    Palleschi, Michela
    Simonelli, Matteo
    Duhoux, Francois P.
    Tosi, Diego
    Uribe, Bernard Doger De Speville
    Gilarranz, Yolanda Jerez
    Tassone, Pierfrancesco
    Curigliano, Giuseppe
    Waters, Simon
    Aftimos, Philippe
    Wildiers, Hans
    Scartoni, Simona
    Vallespir, Bartomeu Piza
    Shankaraiah, Ram Charan
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    CANCER RESEARCH, 2023, 83 (05)
  • [37] Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
    Vuylsteke, P.
    Huizing, M.
    Petrakova, K.
    Roylance, R.
    Laing, R.
    Chan, S.
    Abell, F.
    Gendreau, S.
    Rooney, I.
    Apt, D.
    Zhou, J.
    Singel, S.
    Fehrenbacher, L.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2059 - 2066
  • [38] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos H., Sr.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva M.
    Bianchini, Giampaolo
    Barrios, Carlos H.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
    Rugo, Hope S.
    Turner, Nicholas
    Chia, Stephen
    Ciruelos, Eva
    Nienstedt, Carolyn
    Ridolfi, Antonia
    Kong, Oliver
    Sankaran, Banu
    Juric, Dejan
    CANCER RESEARCH, 2018, 78 (04)
12345